2015
DOI: 10.1200/jco.2014.59.7211
|View full text |Cite
|
Sign up to set email alerts
|

National Guidelines and Level of Evidence: Comments on Some of the New Recommendations in the American Society of Clinical Oncology and the College of American Pathologists Human Epidermal Growth Factor Receptor 2 Guidelines for Breast Cancer

Abstract: TO THE EDITOR: Whenever possible, guideline recommendations should be based on compelling published evidence. Where a recommendation is not supported by such evidence, the guidelines should explicitly state the weaknesses in the evidence, whether the recommendation is based on unpublished evidence, or whether the authors have made a pragmatic decision. This information is particularly important if the recommendations have implications for health care resources. The American Society of Clinical Oncology and the… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
14
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
7
3

Relationship

1
9

Authors

Journals

citations
Cited by 36 publications
(14 citation statements)
references
References 10 publications
0
14
0
Order By: Relevance
“…Rakha et al [36] stated that updated ASCO/CAP 2013 guidelines modified the criteria for equivocal (2+) IHC category by including weak/moderate incomplete membranous staining in more than 10% of tumor cells, which was considered negative in previous guidelines. The author states that no evidence has been provided for such a change, which would result in significant proportion of reflex testing with financial implications.…”
Section: Discussionmentioning
confidence: 99%
“…Rakha et al [36] stated that updated ASCO/CAP 2013 guidelines modified the criteria for equivocal (2+) IHC category by including weak/moderate incomplete membranous staining in more than 10% of tumor cells, which was considered negative in previous guidelines. The author states that no evidence has been provided for such a change, which would result in significant proportion of reflex testing with financial implications.…”
Section: Discussionmentioning
confidence: 99%
“…Rakha et al has also stated that ASCO/CAP 2013 updated guidelines has changed the criteria for equivocal (2+) IHC category by including weak/moderate incomplete membranous staining in more than 10% of tumor cells, which was considered negative in previous guidelines. The author states that no evidence is provided for such a change, which would result in high proportion of reflex testing by in situ hybridization.…”
Section: Discussionmentioning
confidence: 99%
“…We have written a letter to the journal publishing the ASCO/CAP HER2 guidelines, summarizing the above results. 16 In response, the guideline authors will change the section on concordance in grade 3 carcinomas to state that 'If the initial HER2 test result in a core needle biopsy specimen of a primary breast cancer is negative, a new HER2 test "may" be ordered on the excision specimen.' 17 The review of repeat testing in our routine practice supported the recommendation of repeat testing if the tumour in the NCB shows borderline negative amplification.…”
Section: Discussionmentioning
confidence: 99%